Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free ONCT Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Oncternal Therapeutics (ONCT) Competitors

Oncternal Therapeutics logo
Compare

ONCT vs. EGRX, AKTX, TCRT, ACXP, and QUCY

Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Eagle Pharmaceuticals (EGRX), Akari Therapeutics (AKTX), Alaunos Therapeutics (TCRT), Acurx Pharmaceuticals (ACXP), and Mainz Biomed (QUCY). These companies are all part of the "pharmaceutical products" industry.

How does Oncternal Therapeutics compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

In the previous week, Eagle Pharmaceuticals' average media sentiment score of 0.00 equaled Oncternal Therapeutics'average media sentiment score.

Company Overall Sentiment
Eagle Pharmaceuticals Neutral
Oncternal Therapeutics Neutral

Eagle Pharmaceuticals has higher revenue and earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$257.55M0.02$35.64M$1.180.32
Oncternal Therapeutics$790K1.97-$39.48M-$11.69N/A

Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eagle Pharmaceuticals has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Eagle Pharmaceuticals' return on equity of 0.00% beat Oncternal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eagle PharmaceuticalsN/A N/A N/A
Oncternal Therapeutics -1,599.95%-177.58%-131.30%

Summary

Eagle Pharmaceuticals beats Oncternal Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Oncternal Therapeutics compare to Akari Therapeutics?

Oncternal Therapeutics (NASDAQ:ONCT) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Akari Therapeutics has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Akari Therapeutics' return on equity of -70.34% beat Oncternal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oncternal Therapeutics-1,599.95% -177.58% -131.30%
Akari Therapeutics N/A -70.34%-35.46%

16.0% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by company insiders. Comparatively, 30.7% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Akari Therapeutics has a consensus price target of $89.00, indicating a potential upside of 1,252.58%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than Oncternal Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncternal Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Akari Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Akari Therapeutics had 1 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for Oncternal Therapeutics. Oncternal Therapeutics' average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score.

Company Overall Sentiment
Oncternal Therapeutics Neutral
Akari Therapeutics Neutral

Oncternal Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Akari Therapeutics has lower revenue, but higher earnings than Oncternal Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$790K1.97-$39.48M-$11.69N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

Summary

Akari Therapeutics beats Oncternal Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Oncternal Therapeutics compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Alaunos Therapeutics has higher earnings, but lower revenue than Oncternal Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$2.21N/A
Oncternal Therapeutics$790K1.97-$39.48M-$11.69N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Oncternal Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alaunos Therapeutics has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Alaunos Therapeutics has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Alaunos Therapeutics' return on equity of -172.65% beat Oncternal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -172.65% -123.32%
Oncternal Therapeutics -1,599.95%-177.58%-131.30%

In the previous week, Alaunos Therapeutics had 1 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 1 mentions for Alaunos Therapeutics and 0 mentions for Oncternal Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Oncternal Therapeutics'average media sentiment score.

Company Overall Sentiment
Alaunos Therapeutics Neutral
Oncternal Therapeutics Neutral

Summary

Alaunos Therapeutics beats Oncternal Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Oncternal Therapeutics compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Acurx Pharmaceuticals has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Oncternal Therapeutics' return on equity of -177.58% beat Acurx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Acurx PharmaceuticalsN/A -215.54% -128.70%
Oncternal Therapeutics -1,599.95%-177.58%-131.30%

In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 1 mentions for Acurx Pharmaceuticals and 0 mentions for Oncternal Therapeutics. Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Oncternal Therapeutics'average media sentiment score.

Company Overall Sentiment
Acurx Pharmaceuticals Neutral
Oncternal Therapeutics Neutral

Acurx Pharmaceuticals has higher earnings, but lower revenue than Oncternal Therapeutics. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acurx PharmaceuticalsN/AN/A-$7.97M-$5.63N/A
Oncternal Therapeutics$790K1.97-$39.48M-$11.69N/A

Acurx Pharmaceuticals currently has a consensus price target of $31.00, suggesting a potential upside of 1,362.26%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Oncternal Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acurx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Oncternal Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Acurx Pharmaceuticals has a beta of -2.09, suggesting that its share price is 309% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Acurx Pharmaceuticals beats Oncternal Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Oncternal Therapeutics compare to Mainz Biomed?

Oncternal Therapeutics (NASDAQ:ONCT) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncternal Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Oncternal Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

Mainz Biomed has lower revenue, but higher earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$790K1.97-$39.48M-$11.69N/A
Mainz Biomed$540K8.53-$16.21M-$65.60N/A

Mainz Biomed has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Mainz Biomed's return on equity of 0.00% beat Oncternal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oncternal Therapeutics-1,599.95% -177.58% -131.30%
Mainz Biomed N/A N/A N/A

In the previous week, Oncternal Therapeutics' average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score.

Company Overall Sentiment
Oncternal Therapeutics Neutral
Mainz Biomed Neutral

16.0% of Oncternal Therapeutics shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by company insiders. Comparatively, 9.8% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Mainz Biomed beats Oncternal Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Oncternal Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCT vs. The Competition

Export
MetricOncternal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.56M$781.09M$6.31B$12.15B
Dividend YieldN/A4.84%2.78%5.25%
P/E Ratio-0.051.7228.4527.00
Price / Sales1.97119.50531.3876.79
Price / CashN/A20.0743.3053.97
Price / Book0.057.699.836.89
Net Income-$39.48M-$4.80M$3.55B$333.11M

Oncternal Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCT
Oncternal Therapeutics
N/A$0.53
flat		N/AN/A$1.56M$790KN/A30
EGRX
Eagle Pharmaceuticals
N/A$0.48
+25.0%		N/A-80.0%$6.17M$257.55M0.40100
AKTX
Akari Therapeutics
2.1513 of 5 stars		$5.39
-5.9%		$89.00
+1,552.7%		-88.2%$6.17MN/AN/A9
TCRT
Alaunos Therapeutics
0.5367 of 5 stars		$2.52
-2.7%		N/A-8.0%$6.00MN/AN/A40
ACXP
Acurx Pharmaceuticals
2.1081 of 5 stars		$1.97
-4.4%		$31.00
+1,473.6%		-70.1%$5.88MN/AN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ONCT) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Why I flew on a tiny helicopter next to a potential nuclear bomb target
Satellite Confirms: Elon Musk Activating Strange 'Dark Energy' Across U.S. South Confirmed by satellites 30...
Altimetry | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel
I’m sounding the alarm
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel